ArticleBiology direct2026
ALDH18A1 silencing inhibits lung adenocarcinoma progression through mitochondrial dysfunction and PPAR signaling pathway activation.
Article in Biology direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundLung adenocarcinoma (LUAD) remains a prevalent malignant tumor characterized by a dismal prognosis. This study aimed to reveal potential mitochondria-related biomarkers and explore possible mechanisms.
methodsMitochondria-related differentially expressed genes (mitoDEGs) were identified by intersecting LUAD-associated DEGs with mitochondria-associated genes. Hub mitoDEGs were determined via protein-protein interaction (PPI) network analysis and machine learning. Aldehyde dehydrogenase 18 family member A1 (ALDH18A1) was silenced in LUAD cells to investigate its effects on proliferation, invasion, migration, and mitochondrial function. The potential involvement of the peroxisome proliferator-activated receptor (PPAR) signaling pathway in ALDH18A1-associated effects was evaluated in LUAD cells and tumor-bearing mice using the PPARγ antagonist GW9662.
resultsALDH18A1 was identified as a hub mitoDEG and was highly expressed in LUAD.ALDH18A1 silencing promoted apoptosis, suppressed invasion and migration, and inhibited the proliferation of A549 cells. ALDH18A1 silencing induced mitochondrial dysfunction, as evidenced by elevated reactive oxygen species (ROS), diminished mitochondrial membrane potential, decreased ATP production, increased dynamin related protein 1 (DRP1) and mitofusin 2 (MFN2) expression, and decreased optic atrophy 1 (OPA1) in vitro and in vivo. ALDH18A1 silencing increased PPARγ and fatty acid-binding protein 4 (FABP4) expression, whereas GW9662 notably attenuated the antitumor and mitochondrial dysfunction-related effects of ALDH18A1 knockdown.
conclusionALDH18A1 silencing inhibited LUAD progression and induced mitochondrial dysfunction, which may be partly associated with activation of the PPAR signaling pathway. These findings suggest that ALDH18A1 may serve as a candidate mitochondria-related molecular target for LUAD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.